Inclusion criteria:

          -  Males and females greater than or equal to (>=)18 years of age (at the time consent is
             obtained)

          -  Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1 or 2

          -  Diagnosis of non-resectable or metastatic solid malignancy (as defined in the
             protocol) or NHL

          -  Presence of evaluable disease

          -  Adequate organ function (as defined in the protocol)

          -  Reproductive criteria (as defined in the protocol).

        Exclusion Criteria:

          -  Malignancy attributed to prior solid organ transplant

          -  Leptomeningeal disease, spinal cord compression, or brain metastases that require
             immediate central nervous system (CNS)-specific treatment in the opinion of the
             Investigator (for example [e.g.], for symptomatic disease)

          -  History of a second malignancy, excluding non-melanoma skin cell cancer within the
             last three years

          -  Evidence of severe or uncontrolled systemic diseases, or serious and/or pre-existing
             medical or other condition that could interfere with participant's safety, obtaining
             informed consent or compliance to the study procedures, in the opinion of the
             Investigator

          -  Any clinically significant gastrointestinal (GI) abnormalities that may alter
             absorption such as malabsorption syndrome or major resection of the stomach and/or
             bowels.

          -  Select cardiac abnormalities (as defined in the protocol)

          -  History of sensitivity to any of the study medications, or components thereof or a
             history of drug or other allergy that, in the opinion of the investigator or Medical
             Monitor, contraindicates their participation.

          -  History of optic nerve neuropathy or neuritis.